Cancer
Conditions
Interventions
Case series:Mecapegfigrastim injection
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients with clinically diagnosed non-myeloid malignant tumors; 2) Patients receiving treatment regimens that are susceptible to granulocytopenia; 3) Subjects joined the study voluntarily, signed the informed consent, and cooperated with the follow-up. 4) Women of childbearing age must have pregnancy test (serum) within 7 days before admission, and the results are negative. They are willing to use appropriate contraceptive methods during the trial and within 8 weeks after the last administration of the test drug. 5) ECOG PS 0-2.
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) Patients with primary bone tumors and medullary malignant tumors; 3) The patients had other hematological diseases affecting the hematopoietic function of bone marrow; 4) People allergic to biological agents that study drugs or other G-CSF products or the expression of Escherichia coli; 5) According to the judgement of the researcher, the subjects have the accompanying diseases which seriously endanger the safety of the patients or affect the completion of the study; 5) The concomitant diseases that seriously endanger patients'safety or affect patients' completion of the study were judged by the researchers; 6) Other situations that are not suitable for inclusion in this study; 7) Patients who are participating in other clinical trials are not eligible to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test; | — |
Countries
China
Contacts
Public ContactLiu Bo
Shandong Cancer Hospital
Outcome results
None listed